Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK/Safety Study of WAL2014 (Talsaclidine) in Healthy Males
NCT02264067Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1998
- Primary completion
- Nov 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Talsaclidine with Placebo (2 arms). Primary endpoints: Maximum concentration of the analyte in plasma up to 24 hours, Time to reach maximum plasma concentration up to 24 hours and 6 more. Started Jul 1998; status: completed.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02264067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264067.